Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(23)00588-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unusual recurrence in advanced ovarian cancer after interval cytoreductive surgery and HIPEC.
BMJ Case Rep
January 2025
Surgical Oncology, Aster Hospitals Inc, Bangalore, Karnataka, India.
Ovarian cancer is the second most fatal gynaecological malignancy. The relapses after treatment of ovarian cancer usually occur within 2 years after completion of the first-line therapy. Recurrent ovarian cancer commonly presents as peritoneal surface deposits in the abdomen with or without ascites.
View Article and Find Full Text PDFColon and rectal peritoneal carcinomatosis: are we mixing apples with oranges? A propensity score-matched analysis.
Updates Surg
January 2025
General, Emergency and Trauma Surgery, Maurizio Bufalini Hospital, viale Ghirotti 286, 47521, Cesena, Italy.
Rectal cancer is universally considered a different disease entity as compared to colon cancer, except when dealing with colorectal peritoneal carcinomatosis (PC), in which the two cancers are deemed as the same one. The present study aims to investigate the influence of primary tumor location (colon vs. rectum) on oncologic outcomes in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases.
View Article and Find Full Text PDFSurvival outcomes comparing minimally invasive versus open cytoreductive surgery in recurrent adult-type granulosa cell tumors.
Am J Obstet Gynecol
January 2025
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; CPRIT Scholar in Cancer Research. Electronic address:
Background: Adult-type granulosa cell tumors are a rare form of ovarian cancer, 30% of which will recur. Cytoreductive surgery is often performed at the time of a first recurrence, but little is known about the impact of open versus minimally invasive surgical approaches on survival outcomes.
Objective: To examine associations between surgical approach, clinical variables, and survival outcomes among patients with adult-type granulosa cell tumors who underwent cytoreductive surgery at the time of first recurrence.
Current status of postoperative morbidity following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis: a prospective single-center observational study.
Ann Surg Treat Res
January 2025
Department of Surgery, Dankook University College of Medicine, Cheonan, Korea.
Purpose: This study aimed to evaluate current morbidity rates following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer and peritoneal metastasis.
Methods: A total of 42 patients who underwent CRS and HIPEC for colorectal cancer with peritoneal metastasis at a single tertiary referral center between January 2022 and December 2022 were included. Perioperative outcomes and postoperative complications were prospectively assessed.
Controversies around the treatment of peritoneal metastases of colorectal cancer.
World J Gastrointest Oncol
January 2025
Department of General Surgery, Hospital General de Requena, Requena 46340, Spain.
In this editorial we examine the article by Wu published in the . Surgical resection for peritoneal metastases from colorectal cancer (CRC) has been gradually accepted in the medical oncology community. A randomized trial (PRODIGE 7) on cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) failed to prove any benefit of oxaliplatin in the overall survival of patients with peritoneal metastases from colorectal origin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!